drugset / Trial / NCT03006419

Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients

NCT03006419

Phase 4 Completed 100 enrolled Coordinación de Investigación en Salud, Mexico
RandomizedParallel-groupOpen-labelTreatment

Summary

Demonstrate that low dose (3 mg/kg total ) rATG (thymoglobulin) has similar efficacy (delayed graft function, slow graft function, biopsy proven acute rejection episodes, infections, hospitalizations, adverse events, graft loss and death) than Basiliximab induction

Timeline

Start
2016-12-01
Primary completion
2019-07-30
Completion
2019-07-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Basiliximab Monoclonal antibody 20 mg Intravenous
Subject Thymoglobulin Protein / enzyme biologic 1 mg/kg

Indications